OBJECTIVE: To study the long-term efficacy of CAMSBDH- @entity981 chemotherapy protocol for the treatment of childhood @entity981 ( @entity981 ). METHODS: Three hundred and eighteen @entity1 who were newly diagnosed with @entity981 between January 1999 and December 2007 were enrolled in this study. Among the 318 @entity1 , 83 @entity1 who hospitalized before December 2002 were treated with CAMSBDH-ALL99 protocol, including 48 @entity1 of standard risk and 35 @entity1 of high risk. The @entity1 (n=235; 131 in standard risk and 104 in high risk) who hospitalized after December 2002 were treated with CAMSBDH-ALL03 protocol. @entity1 in the CAMSBDH-ALL99 protocol group were treated with conventional chemotherapy. CAMSBDH-ALL03 protocol was modified based on the CAMSBDH-ALL99 protocol. RESULTS: The long-term @entity1349 ( @entity1349 ) and event-free-survival (EFS) in the CAMSBDH-ALL03 group was significantly higher than in the CAMSBDH-ALL99 (P<0.01). The long-term @entity1349 and EFS of standard risk and high risk @entity1 in the CAMSBDH-ALL03 protocol group were significantly higher than in the CAMSBDH-ALL99 protocol group (P<0.01). The CAMSBDH-ALL03 protocol group showed a significantly lower recurrence rate (28.9%) than in the CAMSBDH-ALL99 protocol group (50.6%) (P<0.05). The mortality rate in the CAMSBDH-ALL03 protocol group was 28.5% vs 56.6% in the CAMSBDH-ALL99 protocol group (P<0.05). CONCLUSIONS: The therapeutic effect of the CAMSBDH-ALL03 protocol is supior to the CAMSBDH-ALL99 protocol group for @entity981 , with a higher long-term survival rate.

[Long-term efficacy of CAMSBDH- @entity981 chemotherapy protocol for the treatment of childhood XXXX ].

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['childhood ALL', 'ALL', 'acute lymphoblastic leukemia'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']
